Notably, the combination of cobolimab plus dostarlimab demonstrated an ORR of 46% in patients with PD-1–naïve hepatocellular carcinoma (41) and 43% in patients with PD-1–naïve melanoma (36). This evidence concerns the gene PDCD1 and melanoma.